L-Glutathione Reduced
-
Post Date:
Jan 01,2025
-
Expiry Date:
Jan 01,2026
-
Detailed Description:
Cas No. :70-18-8
Quantity: 1000
Specs:98%~101%
Payment Method: L/C,D/A,T/T
Glutathione is a non-protein sulfhydryl tripeptide compound formed by glutamic acid, cysteine and glycine through peptide bond condensation. It is an active short peptide with wide usage.
GSH is An Irreplaceable Antidote。
GSH is a Crucial Immunpotentiator。
GSH is Excellent Anti-ageing and Beautifying Brightening Agent。
There are a large number of documents about GSH clinical application, which indicates the curative effects in following fields:
1) GSH’s effect on hepatic diseases: it can treat virus hepatitis, alcoholic liver disease, NAFLD, hepatocirrhosis, and DILI, etc.
2) Renal diseases;
3) Protective action to drug-included renal and hepatitis
4) Acute pancreatitis systemic inflammatory response syndrome;
5) Cure diabetes mellitus and DPN;
6) Adjuvant drug in antineoplaston;
7) GSH cures age-related eye diseases;
8) GSH’s protection to intestinal trace;
9) GSH cures anaphylactoid purpura;
10) Treatment to neonatal HIE;
11) Sharing with anticancer drugs: recently, it arouses increasing concern from clinical experts to restrain the side effects of anticancer drugs and strengthen curative effect and host resistance in combination of anticancer drugs;
12) Detoxication: GSH has detoxication to intoxication of medicine, food, heavy metal and carbon monoxide;
13) Anti-ageing ;
-
CAS Registry Number:
70-18-8
-
Synonyms:
;gamma-L-Glutamyl-L-cysteinylglycine;GSH;Glutathione, Reduced, Free Acid;Glutathione reduced;L-Glutathione;Glutathione, reduced;Antisense compounds;Glutathion;5-l-glutamyl-l-cysteinylglycine;ReducedGlutathione;gamma-glutamylcysteinylglycine;L-gamma-glutamyl-L-cysteinylglycine;L-gamma-glutamyl-3-sulfido-L-alanylglycine;{[N-(2-ammonio-4-carboxybutanoyl)cysteinyl]amino}acetate;L-Glutathione (Reduced Form);L-Glutathione Reduced;
-
Molecular Formula:
C10H17N3O6S
-
Molecular Weight:
307.3235
-
Molecular Structure:
-
Safety Description:
S24/25:;
Inquiry